Sagimet Biosciences (SGMT)
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment...
- Open
- 10.220
- High
- 10.480
- Low
- 10.055
- Prev. Close
- 10.180
- Volume
- 492.87K
- Turnover
- 5.08M
- Avg Price
- 10.309
- Bid/Ask Ratio
- -14.40%
- Amplitude
- 4.17%
- 52wk High
- 11.150
- Volume Ratio
- 1.05
- Turnover Ratio
- 0.88%
Sagimet Biosciences Analyst Rating
View moreForecast & Rating
Aug 14, 2026Price forecast
$28.60177.40%
Forecast & RatingStrong buy
10analysts
- Strong buy80.00%
- Buy10.00%
- Hold10.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 17 at 03:28 PM
Sagimet Biosciences grants 260,700 inducement stock options to new hires
- StockTitan · Aug 17 at 07:28 AM
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | SGMT Stock News
- Market Beat · Aug 17 at 03:01 AM
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
- benzinga_article · Aug 14 at 01:11 PM
Sagimet Biosciences shares are trading higher after Citizens raised its price target on the stock from $12 to $29.
- rttnews · Aug 13 at 06:26 AM
Sagimet Biosciences Gets FDA Clearance For Phase 3 Acne Study
- PUBT · Aug 13 at 06:05 AM
Sagimet wins FDA IND clearance for Phase 3 denifanstat acne trial
